Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Congratulations to Professor Arnon on her successful Wellcome Trust Investigator Award entitled: “Spatiotemporal basis of adaptive immunity in the spleen.”

Tal Arnon

Tal has been awarded £1.5 million over 6 years to research how adaptive immune cells navigate between the various functional compartments of the spleen. To study these processes, Tal’s team has pioneered an advanced microscopy technique that allows this analysis inside live intact spleens.

The spleen is the largest immune organ in the body and the only one to filter the blood. It plays a critical role in protection against blood-pathogens, preventing lethal systemic infections. To function optimally, the spleen evolved specialised anatomy and mechanisms that coordinate access of immune cells to sites that regulate their survival and activation.

Speaking of the award Tal said: “I am delighted to receive this award to help us understand how the spleen orchestrates immune responses. These studies may ultimately lead to the development of new vaccine strategies and therapeutic approaches against a variety of immunological diseases.”

Similar stories

Two prestigious Hunterian Professorships awarded to NDORMS researchers

Conrad Harrison and Tom Layton have both been awarded Hunterian Professorships for 2022 by the Royal College of Surgeons of England

Dr Alex Clarke wins Emerging Leaders Prize for lupus research

Alex is one of three exceptional lupus researchers that have been announced as winners of the Medical Research Foundation’s sixth Emerging Leaders Prize.

Adalimumab is found to be a cost-effective treatment for early-stage Dupuytren’s disease

Researchers at the Kennedy Institute of Rheumatology and Oxford Population Health’s Health Economics Research Centre have found that anti-TNF treatment (adalimumab) is likely to be a cost-effective treatment for people affected by early-stage Dupuytren’s disease.

Patients like me

What can patients learn from the experiences of people like them who’ve already had a hip replacement? A new tool called ‘Patients like me’ helps answer some of the questions about pain, complications and how long the prosthesis might last.

Study reveals new evidence on rare blood-clotting condition after covid-19 vaccination

Researchers from NDORMS at the University of Oxford have investigated claims that some adenovirus-based COVID-19 vaccines increase the risk of rare blood clots compared to their mRNA-based counterparts.

NDORMS contributes to new UK research to tackle monkeypox outbreak

The UK’s efforts to tackle the monkeypox outbreak will receive a huge boost with the creation of a new research consortium and a new study to study vaccine effectiveness.